A5080803035- Schizophrenia research and treatment
- Neuroscience and Music Perception
- Neural and Behavioral Psychology Studies
- Neural dynamics and brain function
- Neurotransmitter Receptor Influence on Behavior
- Treatment of Major Depression
- Tryptophan and brain disorders
- Receptor Mechanisms and Signaling
- Bipolar Disorder and Treatment
- Obsessive-Compulsive Spectrum Disorders
- EEG and Brain-Computer Interfaces
- Cannabis and Cannabinoid Research
- Attention Deficit Hyperactivity Disorder
- Neuroscience and Neuropharmacology Research
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Memory and Neural Mechanisms
- Diet and metabolism studies
- Forensic Toxicology and Drug Analysis
- Nicotinic Acetylcholine Receptors Study
- Hearing Loss and Rehabilitation
- Personality Disorders and Psychopathology
- Hip and Femur Fractures
- Hearing, Cochlea, Tinnitus, Genetics
- Takotsubo Cardiomyopathy and Associated Phenomena
- Traumatic Brain Injury and Neurovascular Disturbances
University of California, San Diego
2015-2024
Universidad Católica Santo Domingo
2018
Yale University
2009-2017
VA San Diego Healthcare System
2017
VA Connecticut Healthcare System
2008-2012
Connecticut Mental Health Center
2012
National Institute of Mental Health and Neurosciences
2006-2012
Zucker Hillside Hospital
2010-2012
Memorial Hospital
2006
University of Cincinnati Medical Center
2006
Article Abstract Background: Low nighttime levels of melatonin have been demonstrated in patients with insomnia, and has shown to hypnotic properties some groups such subjects. also observed schizophrenia; however, there is little literature on the efficacy exogenous treating insomnia associated schizophrenia. Method: Stable DSM-IV schizophrenic outpatients (N = 40) initial at least 2 weeks†duration were randomly assigned augment their current medications either flexibly dosed (3-12...
Background: N-methyl-D-aspartate (NMDA) receptor hypofunction has been implicated in the pathophysiology of schizophrenia and its associated neurocognitive impairments. The high rate cigarette smoking raises questions about how nicotine modulates putative NMDA illness. Accordingly, we examined modulatory effects brain nicotinic acetylcholine (nAChR) stimulation on by examining interactive nicotine, a nAChR agonist, ketamine, noncompetitive antagonist, behavioral neurophysiological measures...
Abstract There has been a fundamental failure to translate preclinically supported research into clinically efficacious treatments for psychiatric disorders. One of the greatest impediments toward improving this species gap difficulty identifying translatable neurophysiological signals that are related specific behavioral constructs. Here, we present evidence from three paradigms were completed by humans and mice using analogous procedures, with each task eliciting candidate priori defined...
Targeted cognitive training (TCT) of auditory processing enhances higher-order cognition in schizophrenia patients. TCT performance gains can be detected after 1 session. As a prelude to potential clinical trial, we assessed pharmacological augmentation therapy (PACT) strategy by testing if the psychostimulant, amphetamine, augments speed (APS) patients and healthy subjects (HS). HS were tested screening session (test 1), followed double-blind crossover design (tests 2–3), comparing placebo...
Chronic psychotic disorders, including schizophrenia (SZ), are highly heterogeneous at many levels of analysis, from genetics to clinical presentation and treatment sensitivity. This heterogeneity reflects both a divergence shared biological pathways moving over hundred “risk genes” different phenotypes, the convergence distinct “phenocopies” chronic psychosis. Successful strategies for developing “next generation” interventions in SZ – “pro-cognitive” medications, cognitive remediation,...
Failure of procognitive drug trials in schizophrenia may reflect the clinical heterogeneity schizophrenia, underscoring need to identify biomarkers treatment sensitivity. We used an experimental medicine design test effects a putative agent, tolcapone, using electroencephalogram-based cognitive control task healthy subjects.Healthy men and women (n=27; ages 18-35 years), homozygous for either Met/Met or Val/Val rs4680 genotype, received placebo tolcapone 200 mg orally across 2 days separated...
Muscle relaxants reduce musculoskeletal morbidity with electroconvulsive therapy (ECT) but need to be administered under general anesthesia. The administration of anesthesia is not always possible for patients prescribed ECT. Consequently, unmodified ECT still widely practiced, especially in developing countries.We prospectively assessed consecutive who received bitemporal during a part or the whole their course. All were pretreated an intravenous benzodiazepine (usually diazepam, 10 mg)...